Immune checkpoint inhibitors (ICIs) targeting the programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis have revolutionized the management of advanced and locally advanced non–small cell lung cancer (NSCLC), significantly improving overall survival and long-term disease control [1,2]. This evidence concerns the gene CD274 and lung cancer.